A new experimental mRNA-based vaccine could give a baseline level of immune memory against diverse flu strains: and thus might serve one day as a general preventative measure against future flu pandemics, according to researchers.
Moderna announced today that it is expanding its pipeline of innovative vaccines with three new development programs based on the 'clinical success' of its infectious disease vaccine portfolio to date.
Sanofi warns that the World Health Organization’s delayed strain selection will push back the date on which it delivers vaccines for the 2019-2020 flu season.
